NCT04008901View on ClinicalTrials.gov

"The Efficacy and Safety of BST104 (Lonicera Flos Extract) in Mild to Moderate Functional Dyspepsia Subjects"

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 13, 2017

Primary Completion Date

July 2, 2018

Study Completion Date

November 8, 2018

Conditions

Functional DyspepsiaIrritable Bowel Syndrome

Interventions

DRUG

BST-104 (Lonicera Flos Extract)

175 mg of Lonicera Flos extract in 1 tablet (300 mg)

DRUG

Placebo oral tablet

0 mg of Lonicera Flos extract in 1 tablet (300 mg)

Trial Locations (1)

463-707

Seoul National University Bundang Hospital, Seongnam-si

All Listed Sponsors

lead

Seoul National University Bundang Hospital

OTHER

NCT04008901 - "The Efficacy and Safety of BST104 (Lonicera Flos Extract) in Mild to Moderate Functional Dyspepsia Subjects" | Biotech Hunter | Biotech Hunter